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SUMMARY
The knowledge of mechanisms responsible for acquired sensorineural hearing loss in children, such as viral and bacterial infections, noise 
exposure, aminoglycoside and cisplatin ototoxicity, is increasing and progressively changing the clinical management of affected patients. 
Viral infections are by far the most relevant cause of acquired hearing loss, followed by aminoglycoside and platinum derivative ototoxicity; 
moreover, cochlear damage induced by noise overexposure, mainly in adolescents, is an emerging topic. Pharmacological approaches are 
still challenging to develop a truly effective cochlear protection; however, the use of steroids, antioxidants, antiviral drugs and other small 
molecules is encouraging for clinical practice. Most of evidence on the effectiveness of antioxidants is still limited to experimental models, 
while the use of corticosteroids and antiviral drugs has a wide correspondence in literature but with controversial safety. Future therapeutic 
perspectives include innovative strategies to transport drugs into the cochlea, such as molecules incorporated in nanoparticles that can be 
delivered to a specific target. Innovative approaches also include the gene therapy designed to compensate for abnormal genes or to make 
proteins by introducing genetic material into cells; finally, regenerative medicine (including stem cell approaches) may play a central role 
in the upcoming years in hearing preservation and restoration even if its role in the inner ear is still debated.
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RIASSUNTO 
La conoscenza dei meccanismi fisiopatologici delle condizioni responsabili dell’ipoacusia acquisita nei bambini, tra cui le infezioni virali 
e batteriche, l’esposizione al rumore, l’ototossicità da chemioterapici ed antibiotici aminoglicosidici, è in costante aumento e sta portando 
ad un progressivo cambiamento della gestione diagnostica e clinica del bambino ipoacusico. Le infezioni virali rappresentano la causa più 
frequente di sordità infantile acquisita, seguita dalla tossicità di antibiotici e chemioterapici; mentre l’esposizione al rumore, soprattutto 
negli adolescenti, rappresenta un fattore emergente. Le terapie farmacologiche protettive attualmente in uso includono steroidi, antiossi-
danti, antivirali; l’efficacia degli antiossidanti è ancora in fase di conferma clinica anche se vi sono significative evidenze sperimentali, 
mentre i farmaci steroidei ed antivirali sono certamente validi seppur la loro tossicità sistemica rappresenti ancora un problema non chia-
rito per i quali la somministrazione locale potrebbe rappresentare una possibile evoluzione. Le prospettive di ricerca future includono l’uso 
di nanoparticelle per veicolare molecole direttamente nel sito di danno; inoltre, la terapia genica con l’inserimento di materiale genetico 
all’interno delle cellule per la cura di condizioni da alterazione del patrimonio genetico con la produzione di proteine normali,  potrebbe 
svolgere un ruolo rilevante nella cura e soprattutto nella prevenzione delle sordità acquisite; infine, la terapia rigenerativa e l’impianto 
delle cellule staminali, nonostante il  loro ruolo nell’orecchio interno sia ancora dibattuto, per le notevole limitazioni del loro impiego, 
potrebbe trovare un ruolo nei processi riparativi più che nella differenziazione in cellule sensoriali.
PAROLE CHIAVE: Ipoacusie acquisite • Otorinolaringoiatria pediatrica • Diagnosi genetica • Impianto cocleare
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Introduction
Advances in the development of diagnostic tools, neu-
roimaging techniques and molecular biology are rapidly 
changing the landscape of management in children affect-
ed by sensorineural hearing loss (SNHL) 1; new cases of 
idiopathic hearing loss (HL) are significantly decreasing 
thanks to the introduction of diagnostic and therapeutic 
tools that go well beyond the traditional audiological ex-
amination and contribute to more accurate diagnosis and 
selective therapeutic approaches 2. In the past, treatment 
of SNHL in children was performed exclusively with the 
use of hearing aids; in recent years, cochlear implants 
have radically changed the prognosis of deafness, and 
now play a central role in treatment of SNHL 3.
The better understanding of the mechanisms involved in 
the acquired HL in children, such as viral and bacterial in-
fections, noise exposure, aminoglycoside and cisplatin oto-
toxicity, gives way to innovative therapeutic approaches. It 
is becoming evident that oxidative stress is a final common 
endpoint for complex converging events, some genetically 
determined and some triggered by different stressors. These 
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pathways of oxidative stress are the major causes of most 
types of SNHL, including hereditary drug-induced- and 
noise-induced HL 4-7. At the same time, advances in molec-
ular analysis and identification of new genetic alterations 
play a significant role in the improvement of aetiological 
classification 8 9 and identification of different sensitivity to 
exogenous factors of specific genotypes and how they in-
fluence susceptibility to ototoxicity in children exposed to 
chemotherapeutic agents and antibiotics 10-14.
Therapeutic approaches targeting the mechanism of coch-
lear damage are challenging, while hearing research is fo-
cusing on new strategies for treatment including the regen-
eration of neural epithelium and ganglion neurons through 
gene therapy, implantation of stem cells, and reactivation of 
the processes of cell differentiation 15. In this paper, current 
pharmacological approaches will be reviewed. 
Current pharmacological approaches
Corticosteroids
Cochlear inflammation in children has been observed in 
several pathophysiological conditions, such as electrode 
insertion during cochlear implant surgery, bacterial men-
ingitis, labyrinthitis, otitis media, cisplatin treatment and 
autoimmune diseases 16. TNF-alpha is a key pro-inflam-
matory and pro-apoptotic molecule in the cochlea, re-
leased both by fibroblasts in the spiral ligament and by 
outer hair cells and supporting cells in response to stress 
factors  17. As seen in conditions such as HL following 
meningitis, inflammatory mechanisms can induce dam-
age of the spiral ligament, death of hair cells, ossification 
of the cochlea and disruption of cochlear homeostasis 18.
On this basis, it is well known that systemic administration 
of steroids, such as dexamethasone, methylprednisolone 
and triamcinolone, is the most common clinical approach 
for cochlear inflammation in children. This approach is 
established on the empirical data and experimental ob-
servations of anti-inflammatory and immune suppressive 
activity of these molecules in the cochlea 19 20. However, 
the serious side effects of systemic administration can be 
avoided by local intratympanic administration or intrac-
ochlear application of polymers through the round win-
dow or by a micro-osmotic pump 21 22.
As previously described, protection from electrode inser-
tion trauma in cochlear implantation represents a common 
condition in which steroid therapy is used 23. Damage can be 
immediate or delayed, due to elevated noise and vibrations 
during surgery, insertion of the array, or activation of im-
munological and inflammatory mechanisms 24. Prolonged 
treatment with steroids seems prevent both early and late 
damage 25. These observations support the clinical use of 
dexamethasone administered through an array to guarantee 
the preservation of residual hearing, an important target in 
cochlear implant surgery. Experimental observations show 
that dexamethasone administered through a cochleostomy 
before implantation reduces signs of inflammation and 
improves the density of ganglion neurons; in addition, the 
availability of the drug increases from 2% to 20% if the 
infusion was performed 1 hour to 30 minutes before sur-
gery 26. An electrode (Nucleus 24 Contour, by Cochlear®) 
having a built-in channel for the administration of steroids 
has been proposed 27, and the reduction of electrode imped-
ance values in patients treated with triamcinolone has been 
shown 28  29. However, it is questionable whether a single 
application of steroids can interfere with a mechanism of 
continued damage and if the application of topical steroids 
may favour chronic problems such as infections. In a recent 
study in an animal model, dexamethasone (4  mg/ml) was 
parenterally delivered via a mini-osmotic pump for either 3 
or 7 days; the delayed administration was more effective in 
preserving hearing than a 3-day delivery 30. 
A major use for steroids in children is treatment, in addi-
tion to antibiotic therapy, of bacterial meningitis. Commu-
nity-acquired bacterial meningitis continues to be a heavy 
toll even in developed countries, despite the implementa-
tion of childhood vaccination programs and effective an-
timicrobial agents. The most common aetiological agents 
are Streptococcus pneumoniae and Neisseria meningitidis. 
Today about two-thirds of cases in Europe and United 
States are pneumococcal meningitis, and despite advances 
in medical care mortality is about 15-30% with neurologi-
cal sequelae, including HL, occurring in about 30-50% 
of surviving patients. It is known that bacteria cause the 
release of pro-inflammatory factors, breakdown of the 
blood-labyrinth barrier and loss of ganglion neurons which 
lead to fibrosis and ossification of the cochlear turns. A re-
cent experimental study demonstrated that administration 
of betamethasone in a model of pneumococcal meningitis 
could reduce SNHL and loss of ganglion neurons 31. How-
ever, in humans, a large series of studies involving nearly 
600 cases in a population from Malawi did not support the 
effectiveness of treatment with dexamethasone 32. In 2010, 
an epidemiological Cochrane analysis concluded that the 
effectiveness of an adjuvant treatment with steroids in chil-
dren in developing countries is quite dissimilar 33. A more 
recent Cochrane review examined the effect of adjuvant 
corticosteroid therapy versus placebo on mortality, HL and 
neurological sequelae in people, providing evidence that 
corticosteroids significantly reduced HL and neurological 
sequelae, but not overall mortality. Surprisingly, corticos-
teroids reduced severe HL in children with Haemophilus 
influenzae meningitis 34.
Over 30 years ago glycerol, a diuretic and hyperosmotic 
agent, was used to reduce the HL sequelae of Haemophilus 
meningitis 35. These results were corroborated by another 
study conducted in Finland, demonstrating equal efficacy 
of glycerol and dexamethasone 36. On the contrary, a re-
cent study showed that both intravenous administration of 
dexamethasone and oral administration of glycerol (or the 
combination of the two) could not prevent HL, suggesting 
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that the children’s general conditions and age are effec-
tive predictors for appearance of HL sequelae 37. Despite 
the extensive use of steroids in treatments of conditions 
including ischaemia, viral infection and reactivation and 
microtrauma, better knowledge on the immuno-system of 
inner ear and the mechanism of immuno-mediated inner 
ear disease are still under needed, and therefore the pre-
cise mechanism of corticosteroids remains unclear. The 
inner ear was considered to be “immune-privileged” and 
to exclude all immunocompetent cells except in the endo-
lymphatic sac; however, recent studies have demonstrated 
the presence of immunoreactive cells placed in other parts 
of the cochlea, mainly macrophages residing in the spiral 
ligament and spiral limbus. Recent advances in inner ear 
immunology are promising for a more rational and effec-
tive use of steroids in inner ear diseases.
Antioxidants
Recently, many antioxidant-based protocols have been 
introduced for multiorgan dysfunction in newborns who 
need intensive care, including hypoxia and reperfusion 
damage, sepsis and ototoxic drug administration. New-
born-preterm infants are susceptible to oxidative damage 
because of the immature antioxidant system and an en-
vironment much richer in oxygen; in addition, the pre-
term infant has increased susceptibility to infection and 
inflammation, which increases oxidative stress. In clini-
cal practice, early markers of oxidative stress indicate 
that prenatal or peri-natal prophylactic use of antioxidants 
could help to prevent or at least reduce oxidative stress re-
lated diseases in newborns. Several protocols with lutein, 
melatonin, oxygen and magnesium and calcium channel 
blockers such as flunarizine have been introduced. Lutein 
administration in newborns, at 12 and 36 hours after birth, 
increases the levels of physiological antioxidant activ-
ity decreasing total hydroperoxides 38. Hypothermia, a 
phenomenon which notoriously slows oxidative metabo-
lism, has been proposed for prevention and treatment of 
hypoxic-ischaemic encephalopathy 39. Interestingly, bili-
rubin showed a protective effect against oxidative stress 
at low levels, but was severely toxic at higher levels. We 
demonstrate that a polyphenol, ferulic acid, in a noise in-
duced damage model, upregulates the expression of the 
haemeoxygenase 1 (HO-1) gene (Fig. 1), which is a phase 
two endogenous antioxidant enzyme with the ability to: 
(i) degrade haeme, which in the presence of ROS gener-
ates lipid peroxidation, (ii) produce biliverdin, which is 
the precursor of bilirubin with antioxidant properties 40.
Numerous studies have documented that continuous noise 
exposure in infants in newborn ICUs induces cochlear 
damage that can be incremented by the synergic effects 
of other stressors including hypoxia/reperfusion and ami-
noglycoside treatment. Paediatricians are encouraged to 
monitor sound in the newborn ICU and within incubators, 
and a noise levels > 45 dB should be avoided. Furthermore, 
an estimated 12.5% of teenagers and adolescents aged 6-19 
years have suffered permanent hearing damage from ex-
cessive exposure to recreational noise. Thus, strategies for 
hearing prevention and protection are desirable. Unfortu-
nately, even if several experimental studies have shown the 
beneficial effects of antioxidant supplementation, limited 
results have been reported in clinical studies. Experimen-
tally, the effectiveness of coenzyme Q10 and N-acetyl-
cysteine has been extensively demonstrated. In a recent 
paper, Fetoni et al. demonstrated that a soluble formulation 
of CoQ10, called Q-ter, significantly reduces mitochondrial 
damage, lipid peroxidation and oxidative damage of cellu-
lar proteins induced by oxidative stress and decreases signs 
of apoptosis 41; these data were confirmed by the same 
authors in which they also evaluated systemic versus tran-
stympanic modality 42 43. In addition, in a pilot prospective 
study, randomised and double-blinded, significant hearing 
protection was shown in a group of young volunteers that 
received Qter 200 mg once a day for 7 days before expo-
sure to white noise at 90 dB HL for 15 minutes 44. 
N-acetylcysteine (NAC) is a derivative of cysteine that 
acts as an augmenter of the antioxidant glutathione re-
serves in the body. NAC is used as a mucolytic agent 
and in the treatment of diseases and conditions caused 
by oxidative stress, such as paracetamol toxicity and ne-
phropathy induced by contrast agents 45. In vivo studies 
have shown that NAC works as a scavenger of ROS, but 
its main antioxidant activity derives from being a pre-
cursor of cysteine, itself a precursor in the formation of 
glutathione. In addition, NAC protects against mitochon-
drial damage and reduces glutamate excitotoxicity both in 
outer hair cells and dendrites of afferent neurons. NAC is 
one of the few molecules tested in clinical trials involv-
ing children affected by acoustic trauma. In a randomised 
placebo-controlled double-blind study including a popu-
lation of adolescents exposed to loud music, oral NAC 
Fig. 1. Polyphenols can activate the Nrf-2/HO-1 pathway. We have demon-
strated that many polyphenols (ferulic acid, curcumin) can potentiate endog-
enous antioxidant defenses both in outer hair cells and spiral ganglion neu-
rons, promoting inactivation of the Nrf2-Keap1 complex. As a consequence, 
the enhancement of Nrf-2 nuclear translocation appears to upregulate the 
expression of many Phase-II cytoprotective enzymes (HO-1, SODs). 
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(900 mg single dose) or placebo were given 1 hour before 
exposure to loud music. This study did not demonstrate a 
significant difference on the temporary threshold shift in 
hearing between the treated and placebo groups 46.
Sodium salicylate is a potent antioxidant and anti-inflam-
matory drug with several effects on hearing function 47. Sa-
licylate hydroxyl groups destroy free radicals and promote 
translocation of the anti-apoptotic transcription factor NF-
kB, preventing HL and cochlear damage especially when 
induced by aminoglycosides 48 and cisplatin 49. In a double-
blind controlled study involving patients treated with gen-
tamicin for acute infections, aspirin at a dose of 3 g/day 
for 14 days showed a significant level of hearing protection 
compared with placebo  50. However, long term treatment 
with salicylate has been reported to impair auditory neural 
activity 51 and to induce tinnitus and HL 52 53. Antioxidants 
represent the most rational and safe approach for treatment 
of SNHL, although more data from clinical trials is needed 
for better knowledge of doses and timing of treatment.
Protective agents against cisplatin-induced ototoxicity
Platinum compounds form the mainstay of currently used 
chemotherapeutic regimens for several malignancies in 
paediatric patients, such as neuroblastoma, germ-cells 
tumours, osteosarcomas, hepatoblastomas, brain tumours 
and relapsed and refractory lymphomas. Debilitating dose 
dependent side effects include nephrotoxicity, myelosup-
pression, neurotoxicity and HL. Although deafness is 
not a life-threatening condition and its degree is highly 
variable, HL causes communicative disorders in affected 
children that can result in a poorer quality of life. Thus, 
the development of effective strategies with protective 
molecules acting on the side effects without affecting or 
decreasing antitumour activity is recommended. 
Several studies have demonstrated the effectiveness of 
sodium thiosulphate (STS) protection against cisplatin 
cytotoxicity  54  55. This molecule acts through its thiolic 
groups as a chelator of cisplatin, forming an inactive com-
plex that prevents the absorption of cisplatin into the cell; 
unfortunately, differently from animal study results, the 
drug has been reported to reduce the effectiveness of sys-
temic cisplatin therapy 56. However, it has been shown that 
treatment with a delayed high dose of intravenous STS in 
children with malignant brain tumours a few hours after 
administration of carboplatin results in hearing protec-
tion without affecting the antineoplastic effect of cisplatin 
through alteration of the blood-brain barrier system 57.
WR1065, the active metabolite of amifostine, has shown 
remarkable radio- and chemoprotective effects both in vit-
ro and in vivo 58. The conversion of amifostine to WR1065 
is catalysed by alkaline phosphatase and depends on the 
presence of alkaline pH. Differences in the concentration 
of alkaline phosphatase of normal versus cancer tissues 
can result in greater conversion of amifostine in normal 
tissues, providing relatively selective cytoprotection. The 
timing of the drug administration is an important factor 
for its protective efficacy and only limited pharmacokinet-
ic data are available for children 59 60. Data from literature 
are often contradictory and several clinical reports focus 
on the peripheral neurotoxicity without studying HL. 
Other protective drugs have been experimented in animal 
and human studies during the past few years; these include 
alpha-lipoic acid 61, trichostatin A 62, oxytocin 63, resvera-
tol 64, hesperetin 65 and lutein 66. However, data are prelimi-
nary and have not been confirmed. From a critical reading 
of the literature, a lack of knowledge of the pharmacoki-
netic mechanisms, particularly in children, and a lack of 
data on dosage and ways of administration appear to be the 
main obstacles. Interestingly, attention has been more re-
cently focused on the opportunity of molecular targeted ap-
proaches for cancer prevention and therapy and the use of 
adjuvant chemotherapeutics to overcome the limitations of 
cisplatin. Owing to their safe use, some polyphenols, such 
as curcumin, might modulate important pathways or mo-
lecular targets in cancers. We evaluated curcumin as an ad-
juvant molecule to cisplatin, demonstrating that curcumin 
attenuated all stages of tumour progression (survival, pro-
liferation) and, by targeting pSTAT3 and Nrf-2 signalling 
pathways, provided chemosensitisation to cisplatin in vitro 
and protection from its ototoxic adverse effects in vivo. In 
the perspective of a personalised approach of cancer thera-
py, the beneficial effects of curcumin as an adjuvant agent 
to cisplatin offer strong preliminary data for clinical studies 
in humans 67. Innovative approaches modulating the chem-
oresistence to cisplatin and acting in the prevention of its 
side effects is challenging for the future of antineoplastic 
therapy, especially in children who are more sensitive than 
adults to adverse effects such as ototoxicity. 
Antiviral therapy for CMV infection
CMV is also a major cause of morbidity and occasional 
mortality in newborn infants. In recent years, it has be-
come evident that CMV is the most important cause of 
congenital infection in the developed world, and that it 
frequently leads to mental retardation and developmental 
disability including HL and neuro-developmental delay. 
The incidence of congenital CMV infection ranges from 
0.5% to 2% of all live births. Maternal CMV seroprev-
alence varies widely, ranging from 45% to 100%, with 
higher prevalence and earlier CMV acquisition associated 
with lower socioeconomic status. Transmission can occur 
in mothers with no evidence of CMV immunity (primary 
infection) and in women with preexisting antibodies either 
by reactivation of previous maternal infection or by acqui-
sition of a different viral strain during pregnancy. Primary 
maternal CMV infection during pregnancy is associated 
with a greater risk of in utero transmission, although 
about two-thirds of infants with congenital CMV infec-
tion are born from mothers with preexisting antibodies 
against CMV. Among congenitally CMV infected infants, 
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approximately 10-15% are symptomatic at birth. Clinical 
manifestations range from mild and transient symptoms 
to severe multi-system dysfunction including intrauterine 
growth restriction, petechiae, jaundice, hepatospleno-
megaly, microcephaly, chorioretinitis and SNHL, which 
represents the most common non-genetic cause of SNHL. 
It has been estimated that HL occurs in nearly 50% of in-
fants with symptomatic congenital CMV infection, while 
7% of asymptomatically infected infants develop HL with 
delayed onset, or a progressive or fluctuating course 68.
The measure of viral load, as determined by polymerase 
chain reaction (PCR) assay in blood, is a biomarker and a 
predictor of sequelae development. The effectiveness of con-
trol of viral infection during pregnancy and in the perinatal 
period is essential in decreasing early and late disorders and 
mortality. At present, there are no approved treatments dur-
ing pregnancy to prevent or ameliorate the severity of foetal 
CMV infection. However, ongoing trials are studying treat-
ment with hyperimmune globulin (HIG), pooled intravenous 
immunoglobulin and antiviral drugs to prevent mother-to-
child transmission and ameliorate foetal sequelae. Currently, 
four antiviral drugs are available against CMV: ganciclovir, 
valganciclovir, foscarnet and cidofovir. Treatment with an-
tiviral drugs cannot be recommended for use during preg-
nancy because of the limited evidence on their safety and 
efficacy 69. Due to the increasing incidence of CMV infec-
tion, the need for antiviral therapy in infants and children 
is growing, and progresses in vaccine therapy will probably 
lead to the eradication of the infection 70. Although there are 
limited data on the dosage, pharmacokinetics, safety and risk 
of adverse effects for some of these antiviral agents, the sys-
temic administration of ganciclovir, due to its low oral avail-
ability, and its oral prodrug valganciclovir, have been exten-
sively studied in the newborn 71. Among adverse effects, it is 
important to highlight renal toxicity, which is irreversible for 
cidofovir and foscarnet, and neutropenia, more frequently 
associated with ganciclovir and valganciclovir. In addition, 
these drugs have other potentially serious toxic effects such 
as carcinogenicity, teratogenicity and azoospermia and dep-
osition in bone or teeth (foscarnet) that may have significant 
implications when used in children 72.
For these reasons, antiviral treatment should be reserved to 
severe cases. The most common treatment is intravenous 
ganciclovir (12 mg/kg/d in 2 doses), whereas oral adminis-
tration of valganciclovir (32 mg/kg/d in 2 doses) could be 
an alternative in some cases 73. However, there is a lack of 
clinical experience in the post-natal period; there is little 
evidence of efficacy and pharmacokinetic studies are lack-
ing in premature infants 74. Duration of therapy is a contro-
versial factor, as it should be continued for at least 2 to 6 
weeks for intravenous therapy and up to 6 months for oral 
therapy; duration of treatment should be correlated with 
PCR monitoring 75. Prophylaxis or treatment with acquired 
infection immunoglobulin in preterm infants showed no 
benefit to justify its use in all children. The treatment of 
children with early infection is effective in reducing HL in 
case of brain infection manifestations, but has been shown 
to be ineffective in asymptomatic infections. In a retrospec-
tive paper, it appears that about 90% of children maintain 
or enhance normal hearing after treatment, while the data 
on the efficacy of treatment in children with late diagnosis 
of HL are still limited 76. Serological testing in at-risk preg-
nant women is recommended in prevention of conceptional 
infection, and identification in early pregnancy by serologi-
cal testing may improve outcomes for CMV prevention 69. 
Trials are needed to demonstrate the effectiveness of the 
use of antiviral molecules in less severe disease. The ab-
sence of guidelines is a major problem for management 
of CMV infection; however, the International Congenital 
Cytomegalovirus Recommendations Group has recently 
provided recommendations for prevention, diagnosis and 
treatment that are summarised in Figure 2 77.
New perspectives in HL in children
Nanoparticles 
The use of nanoparticles has rapidly increased in hearing 
research in the past decade and probably represents the 
experimental approach that is closest to clinical applica-
tions for drug, peptide or gene therapy. In the inner ear, the 
most studied nanoparticles are biodegradable liposomes, 
nanocapsules and lipid micelles. The history of nano-
particles is quite recent and there are still many doubts 
concerning the type of nanoparticles, their stabilisation, 
their ability to reach and bind the target and their cochlear 
degradation. Recent experimental studies focused on the 
use of polyethyleneimine (PEI) and poly lactic-glycolic 
acid (PLGA); however, PEI was highly toxic and PLGA 
is still undergoing safety studies 78. Lipid nanocapsules 
(LNCS), thanks to their lipoprotein-like structure with 
an oily core, show good distribution in the inner ear after 
application to the round window membrane 79 and pro-
longed stability that permits close control on the dynamic 
release of the carried molecules. Interestingly, it has been 
demonstrated that lipid nanoparticles conjugated with a 
neurotrophic peptide focus selectively on the cells of the 
inner ear of mice 80. However, the main concern about 
nanoparticles is their biocompatibility and intracochlear 
toxicity: in a recent study, it was shown that in vivo ad-
ministration of lipid nanoparticles did not cause hearing 
damage or morphological changes in the inner ear 81. In 
conclusion, nanoparticles can be equipped with target-
ability, immuno-transparency, although their application 
in clinical practice is still limited by possible side effects.
Gene therapy
Gene therapy has the goal to introduce a new or a regulatory 
gene in a target cell to replace or repair the defective gene 82. 
Due to the risk of nucleic acid degradation related to the ac-
tion of nucleases that recognise a foreign gene, gene therapy 
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should be administered in a protected environment by an ap-
propriate vehicle leading itself to the target cell.
Two basic types of approaches have been proposed: the in-
troduction of protective genes and the activation of transdif-
ferentiation genes. Many investigations have recently shown 
the success of transfection and expression of neurotrophic 
factors in the inner ear by viral and non-viral vectors admin-
istered through cochlear implants. Neurotrophic factors play 
a crucial role in differentiation, proliferation, development, 
neuronal plasticity and cell survival in embryonic develop-
ment and throughout life. About 20 neurotrophic factors have 
been studied; among these, 
the neurotrophin family 
(NT-3 and 7), glial growth 
factor (GDNF glial cell line-
derived neurotrophic factor), 
brain (brain-derived neuro-
trophic factor BDNF), plate-
let (platelet-derived growth 
factor PDGF) and insulin 
neurotrophic factors [(IGF, 
insulin-like growth factor 
(IGF)] have been extensively 
studied in improving spiral 
ganglion neurons survival 
after cochlear implanta-
tion 83 84.
The success of gene therapy 
depends on the carrier of 
the gene and both viral or 
non-viral carriers have been 
used. Adenovirus 4 5, Ad-
eno-associated viruses  6-8, 
Lentivirus  9, type 1 Herpes 
simplex virus and Vaccinia 
virus 10 11 have all shown 
promising results. However, 
their use is coupled with 
a high potential for toxic-
ity, immunogenicity and/
or mutagenicity. Non-viral 
vectors are safer and offer 
greater possibilities for ma-
nipulation and more flex-
ibility for the transfected 
gene size; among these, the 
most important candidates 
as carriers are nanoparticles 
and nanolipidic-capsules 
that could be applied to the 
round window. However, 
their poor nuclear localisa-
tion in cochlear cells limits 
their application in gene 
therapy. Although gene 
therapy is a promising treatment option, its application is 
currently limited by the risk of side effects and is still under 
study to ensure that it will be safe and effective.
Stem cells
Transplantation of progenitor cells capable of differentia-
tion into functional hair and/or spiral ganglion cells is un-
doubtedly a fascinating strategy. Embryonic, foetal, cord 
blood, central nervous system, placental stem cells or adult 
cells of the inner ear have been shown to differentiate into 
cells such as hair cells with mechano-sensitive functioning 
Fig. 2. Flow chart to identify an intrauterine cytomegalovirus-infected infant and recommendations for appropriate 
treatment (modified from Rawlinson et al, Lancet 2017).
AI, avidity index; ABR, auditory brain stem response; IgG, immunoglobulin G; IgM, immunoglobulin M; US, ultra-
sonography. 
*When AIs were measured, maternal sera collected at first trimester were used
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cilia in vitro 85. More recently, Koehler et al. have pub-
lished the generation in 3D culture of functioning inner 
ear sensory epithelia from pluripotent stem cells; they 
reported that these stem-cell-derived hair cells exhibit 
functional properties of native mechanosensitive hair 
cells and form specialised synapses with sensory neu-
rons that have also arisen from mouse embryonic stem 
cells in the culture 86.
Several laboratories have begun to study the implanta-
tion of these cells in models of deafness. At present, only 
limited survival has been shown for implanted cells in 
vivo; in rare cases, these cells became host integrated. 
Despite much evidence for differentiation into mature 
cell types, there has been no clear demonstration that 
hair cells can have functional recovery 87. However, it 
remains to be accurately determined if stem cells can 
differentiate into hair cells or rather, more likely, they 
can promote reparative and trophic effects on sensori-
neural epithelia, stria vascularis and spiral ganglion neu-
rons, limiting the regenerative effects on the supporting 
cells 15 87 88.
Conclusions
Although considerable progresses have been made in 
recent years, pathways for hearing preservation and res-
toration in children are still controversial. The progres-
sively increasing knowledge about the pathophysiological 
mechanisms underlying cell death and reparation, inner 
ear genetics and development of new technologies to de-
liver therapies into a specific target represents a solid ba-
sis for research in this field. 
The literature shows more than 110 molecules proposed 
to date in the prevention or repair of cochlear damage 
by exogenous factors; however, for most of these drugs, 
their use is not supported by clinical data. Corticosteroids 
represent a milestone for treatment of SNHL in children, 
even if there are no guidelines or indications for their use 
in children. Antiviral therapy for CMV infection may re-
duce the incidence of the most common cause of acquired 
sensorineural hearing loss, while research for a CMV 
vaccine is continues to be challenging. The possibility of 
combining nanotechnologies with cochlear implants for 
the application of targeted molecules or gene is probably 
the most attractive perspective for the near future. Finally, 
the role of stem cells in the inner ear is still debated, as 
they appear to be more involved in the reparative process-
es rather than differentiating into functioning hair cells.
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